Current Heart Failure Reports

, Volume 1, Issue 2, pp 57–64

Inhibition of RAAS—When is it too much?

Authors

  • Pablo Navarro
  • Robert Moskowitz
  • Thierry H. Le Jemtel
    • Room G-46 Forchheimer BuildingAlbert Einstein College of Medicine
Article

DOI: 10.1007/s11897-004-0026-3

Cite this article as:
Navarro, P., Moskowitz, R. & Le Jemtel, T.H. Curr Heart Fail Rep (2004) 1: 57. doi:10.1007/s11897-004-0026-3
  • 33 Views

Abstract

Deactivation of the renin-angiotensin-aldosterone system (RAAS) is clearly beneficial in patients with recent myocardial infarction and chronic heart failure. Most of the experience with deactivation of the RAAS has been collected in placebo-controlled randomized trials of angiotensinconverting enzyme inhibition (ACEI). The hypothesis that angiotensin receptor blockade may be a better approach to deactivate the RAAS has not survived the test of time. Despite the extensive experience with ACEI and aldosterone receptor blockade in patients with recent myocardial infarction and chronic heart failure, several issues remain unanswered. These are addressed in this review.

Copyright information

© Current Science Inc 2004